---
title: "Analyst Reaffirms Buy on Harrow Health, Citing Expanding Ophthalmic Franchise and Long-Term Growth Pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291429682.md"
description: "William Blair analyst Lachlan Hanbury Brown reaffirmed a Buy rating on Harrow Health (HROW), citing its expanding ophthalmic franchise and long-term growth pipeline. Key drivers include the commercial introduction of Byooviz via a Samsung Bioepis partnership and a growing portfolio of FDA-approved products like Vevye and Iheezo. Despite potential short-term share price fluctuations, the analyst views the company's execution and future products, such as Opuviz, as supporting strong long-term growth. Lake Street also maintained a Buy rating with a $60 price target."
datetime: "2026-07-01T13:45:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291429682.md)
  - [en](https://longbridge.com/en/news/291429682.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291429682.md)
---

# Analyst Reaffirms Buy on Harrow Health, Citing Expanding Ophthalmic Franchise and Long-Term Growth Pipeline

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on HROW stock, giving a Buy rating today.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Lachlan Hanbury Brown has given his Buy rating due to a combination of factors related to Harrow Health’s expanding ophthalmic franchise and recent execution milestones. The commercial introduction of Byooviz, through an exclusive U.S. partnership with Samsung Bioepis, broadens Harrow’s presence in the large anti-VEGF retina market and adds a new, albeit initially modest, revenue contributor.

Beyond Byooviz, Brown highlights Harrow’s growing portfolio of FDA-approved products, including Vevye, Iheezo, and Triesence, which together reinforce the company’s positioning in U.S. ophthalmic pharmaceuticals. While acknowledging that periodic demand patterns may cause share-price fluctuations, he views the company’s execution and product pipeline—such as future commercialization of Opuviz—as underpinning a compelling long-term growth profile that supports a Buy recommendation.

Hanbury Brown covers the Healthcare sector, focusing on stocks such as Harrow Health, Viridian Therapeutics, and Ocular Therapeutix. According to TipRanks, Hanbury Brown has an average return of 1.3% and a 41.30% success rate on recommended stocks.

In another report released today, Lake Street also maintained a Buy rating on the stock with a $60.00 price target.

### Related Stocks

- [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md)
- [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md)
- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)
- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)
- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)

## Related News & Research

- [HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline](https://longbridge.com/en/news/295473527.md)
- [Harrow: Strong Iheezo Demand and Confident 2026 Guidance Support Buy Rating Despite Near-Term Miss](https://longbridge.com/en/news/295460276.md)
- [Harrow Chief Scientific Officer Amir Shojaei disposes of 11,250 common shares worth $450,000](https://longbridge.com/en/news/296149417.md)
- [Harrow Q2 revenue slightly beats estimates](https://longbridge.com/en/news/295445394.md)
- [B. Riley Securities Keeps Their Buy Rating on Harrow Health (HROW)](https://longbridge.com/en/news/295421123.md)